Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies. Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
The company is engaged in developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies, enabling the medical community to effectively combat life-threatening tumors.
B2B
51 to 100
Series B
$172 M
Scaling Up
2018
Biotechnology
N/A
N/A
Service
Yes
Active
Machine Learning
N/A
Software
N/A
Jul 2021
- Wugen Raised $172M in Series B Funding
Apr 2021
- Wugen Hired Daniel Kemp, Ph.D., as Chief Executive Officer
Mar 2021
- Wugen Partnered with Alpha Biopharma in Asia
Mar 2021
- Wugen Announced Exclusive License Agreement With HCW Biologics
Chief Financial Officer
St Louis, MO
Head of NK Process Development
St Louis, MO
Scientist / Engineer: CMC Technology Transfer
St Louis, MO
Associate Director/Director, Clinical Quality Assurance
San Diego, CA
AI/ML Professionals
9
1
$172M
Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round
Investors
Interested in researching Wugen?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Wugen
